Application prospects of mitochondrial pyruvate carrier inhibitors in treatment of metabolic dysfunction-associated steatohepatitis
- VernacularTitle:线粒体丙酮酸载体抑制剂在代谢相关脂肪性肝炎治疗中的应用前景
- Author:
Xinyue CHEN
1
;
Zhenhua ZHOU
2
Author Information
- Publication Type:Review
- Keywords: Metabolic Dysfunction-Associated Steatohepatitis; Mitochondrial Pyruvate Carrier; Therapeutics
- From: Journal of Clinical Hepatology 2026;42(4):938-942
- CountryChina
- Language:Chinese
- Abstract: Metabolic dysfunction-associated steatohepatitis （MASH） is a complex liver disease characterized by abnormal fat accumulation in the liver， accompanied by inflammation and hepatocyte injury， and it can gradually progress to liver fibrosis， liver cirrhosis， and even hepatocellular carcinoma. MASH has a complex pathogenesis involving multiple links such as insulin resistance， de novo lipogenesis （DNL）， oxidative stress， and mitochondrial dysfunction. In recent years， mitochondrial pyruvate carrier （MPC） has attracted wide attention as a key molecular target for regulating lipid metabolism. This article systematically reviews the mechanism of action of MPC in MASH， with a focus on how inhibiting MPC expression regulates lipid synthesis and metabolism by reducing DNL production and modulating signaling pathways such as AMPK-ACC， thereby improving liver inflammation. In addition， this article discusses the potential application prospects of MPC inhibitors in MASH treatment， in order to provide new ideas for future clinical research on MASH management.
